标题/作者	年份
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs DR Tompa, A Immanuel, S Srikanth, S Kadhirvel International journal of biological macromolecules 172, 524-541	2021
Potential therapeutic options for COVID-19: current status, challenges, and future perspectives C Sarkar, M Mondal, M Torequl Islam, M Martorell, AO Docea, A Maroyi, ... Frontiers in pharmacology 11, 572870	2020
Advances in the possible treatment of COVID-19: A review. P Chibber, SA Haq, I Ahmed, NI Andrabi, G Singh European journal of pharmacology 883, 173372	2020
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections SR Bonam, NG Kotla, RA Bohara, Y Rochev, TJ Webster, J Bayry Nano today 36, 101051	2021
The cap-snatching mechanism of bunyaviruses S Olschewski, S Cusack, M Rosenthal Trends in microbiology 28 (4), 293-303	2020
Redox control in the pathophysiology of influenza virus infection KK Chen, M Minakuchi, K Wuputra, CC Ku, JB Pan, KK Kuo, YC Lin, ... BMC microbiology 20 (1), 1-22	2020
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility JC Jones, PNQ Pascua, TP Fabrizio, BM Marathe, P Seiler, S Barman, ... Proceedings of the National Academy of Sciences 117 (15), 8593-8601	2020
Inhaled biguanides and mTOR inhibition for influenza and coronavirus S Lehrer World Academy of Sciences Journal 2 (3), 1-1	2020
High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro AL Gard, RJ Luu, CR Miller, R Maloney, BP Cain, EE Marr, DM Burns, ... Scientific Reports 11 (1), 14961	2021
Potential COVID‐19 therapeutic agents and vaccines: an evidence‐based review E Khani, S Khiali, T Entezari‐Maleki The Journal of Clinical Pharmacology 61 (4), 429-460	2021
Repurposing papaverine as an antiviral agent against influenza viruses and paramyxoviruses M Aggarwal, GP Leser, RA Lamb Journal of virology 94 (6), 10.1128/jvi. 01888-19	2020
Antiviral drugs in influenza M Świerczyńska, DM Mirowska-Guzel, E Pindelska International journal of environmental research and public health 19 (5), 3018	2022
Influence of cellular lipid content on influenza A virus replication N Limsuwat, C Boonarkart, S Phakaratsakul, O Suptawiwat, P Auewarakul Archives of Virology 165, 1151-1161	2020
Brevilin a, a sesquiterpene lactone, inhibits the replication of influenza a virus in vitro and in vivo X Zhang, Y Xia, L Yang, J He, Y Li, C Xia Viruses 11 (9), 835	2019
A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic I Kaur, T Behl, A Sehgal, S Singh, N Sharma, V Subramanian, S Fuloria, ... Environmental Science and Pollution Research 29 (45), 67685-67703	2022
Current and novel approaches in influenza management E Kotey, D Lukosaityte, O Quaye, W Ampofo, G Awandare, M Iqbal Vaccines 7 (2), 53	2019
Host–virus interaction: How host cells defend against influenza a virus infection Y Zhang, Z Xu, Y Cao Viruses 12 (4), 376	2020
Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: an extensive study M Mandal, SK Chowdhury, AA Khan, N Baildya, T Dutta, D Misra, ... Journal of molecular structure 1234, 130152	2021
An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir R O’Hanlon, VH Leyva-Grado, M Sourisseau, MJ Evans, ML Shaw ACS infectious diseases 5 (10), 1779-1793	2019
Toosendanin from melia fructus suppresses influenza A virus infection by altering nuclear localization of viral polymerase PA protein YH Jin, S Kwon, JG Choi, WK Cho, B Lee, JY Ma Frontiers in Pharmacology 10, 1025	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。